Form 4: Praxis GC Nemiroff Reports Equity Awards and Tax Sale

Praxis Precision Medicines' General Counsel, Alex Nemiroff, reported the acquisition of restricted stock units and stock options, alongside a disposition of shares for tax obligations.

Summary

• Alex Nemiroff, General Counsel and Secretary of Praxis Precision Medicines, Inc. (PRAX), reported changes in his beneficial ownership.
• On January 8, 2026, Mr. Nemiroff was awarded 6,875 restricted stock units (RSUs), each representing a contingent right to receive one share of the Issuer's Common Stock.
• These RSUs will vest in equal annual installments over a four-year period, commencing on January 8, 2027.
• Following this RSU award, Mr. Nemiroff's direct beneficial ownership of Common Stock increased to 27,617.667 shares.
• Also on January 8, 2026, Mr. Nemiroff acquired a stock option to buy 5,500 shares of Common Stock with an exercise price of $294.38.
• This stock option vests 25% on January 8, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service.
• The stock option has an expiration date of January 8, 2036.
• On January 10, 2026, Mr. Nemiroff disposed of 917 shares of Common Stock at a price of $288.45 per share.
• This disposition was to satisfy tax withholding obligations related to the vesting of previously reported restricted stock units.
• After the disposition, Mr. Nemiroff's direct beneficial ownership of Common Stock is 26,700.667 shares, and he beneficially owns 5,500 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it reflects routine equity compensation for a key executive, aligning their interests with shareholders. The disposition for tax purposes is a standard event and does not indicate negative sentiment.

Positives

• The award of 6,875 restricted stock units (RSUs) aligns management's interests with shareholder value.
• The grant of a stock option for 5,500 shares further incentivizes long-term performance and retention of key personnel.

Negatives

• A disposition of 917 shares of Common Stock occurred to cover tax withholding obligations, which is a routine event but represents a reduction in direct share ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance or strategic direction, focusing solely on insider equity transactions.

Stakeholder Impact

• Shareholders: The issuance of new equity awards (RSUs and stock options) to a key executive can lead to minor dilution but also strengthens management's alignment with long-term shareholder value. The tax-related sale is a routine event with minimal impact.

Next Steps

• The restricted stock units will vest in equal annual installments over a four-year period, beginning on January 8, 2027.
• The stock option will vest 25% on January 8, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter.

Key Dates

Keywords

Praxis Precision Medicines, PRAX, Alex Nemiroff, Restricted Stock Units, RSUs, Stock Options, Insider Transaction, Equity Awards, Beneficial Ownership, Tax Withholding